RAHWAY, N.J.– The U.S. Environmental Protection Agency (EPA) has announced it has authorized the renewal of its 2021 public health emergency exemption allowing for the use of Grignard Pure™ as the first-ever antiviral air treatment product proven effective at reducing the spread of the COVID-19 virus. Pennsylvania, Texas and Tennessee, three of the six states granted emergency exemption in 2021, received approval of their applications for renewal. Additionally, the EPA approved the emergency exemption for new state applicant, Virginia. Maryland, Georgia and Nevada also were granted emergency exemption authorizations in 2021 and are in the process of finalizing submissions for renewal. Grignard Pure, LLC expects additional states to submit to the EPA for approval. This emergency exemption renewal extends through January 14, 2023.
The EPA initially issued the emergency exemption on January 15, 2021, approving the use of Grignard Pure™ in certain indoor spaces, occupied and unoccupied, where social distancing can be challenging and where the risk of infection is elevated. Grignard Pure™ is proven effective at killing 98% of the SARS-CoV-2 virus in the air, where the CDC has confirmed transmission is most likely. Grignard Pure™ should be part of an overall set of precautions that includes mask wearing, social distancing, vaccination and ventilation. Always follow CDC, state and local public health guidelines.
Grignard Pure, LLC has assembled a network of key partners with national presence and expertise in key verticals, each of whom skilled in the implementation, training and servicing of the technology solution. These partners, who are working toward marketing and selling the Grignard Pure™ solution in the approved states, include:
- Servpro: the country’s leading provider of disaster recovery and remediation and COVID mitigation services.
- Luminator Technology Group: an industry leader in designing globally-recognized technology solutions that increase intelligence, safety and efficiency for public transit operations.
- Veolia Water Technologies, Inc.: leading global experts specializing in water & wastewater treatment solutions for industrial clients and public authorities.
- Columbia Elevator: one of the leading providers of products and solutions to the commercial, LULA and residential segments of the North American elevator industry.
Grignard Pure, LLC and its partners have completed numerous successful installations of the Grignard Pure™ solution in multiple industries and environments including mass transit, medical, industrial and in houses of worship. One such installation, implemented by Veolia, is at Streamline Innovations, based in San Antonio, Texas, which deployed the Grignard Pure™ solution in August, 2021.
“We’re an oil and gas company so we’ve had a lot of exposure both with people out in the field and in our office, including two situations that impacted the business for weeks at a time,” said Katie Rios, Streamline Innovations Corporate Administrator. “We love the technology behind Grignard Pure. It gives everyone that peace of mind knowing that we have all solutions covered for treating COVID and minimizing the exposure to other employees, if someone does happen to walk in who is infected.”
“We recognize the EPA decision to renew is a significant validation of the effectiveness of Grignard Pure in helping stop the spread of the COVID-19 virus,” said Etienne Grignard, founder and CEO, Grignard Pure, LLC. “And while this step also reflects the support and endorsement we’ve received from leading scientists, academics, medical professionals, engineers, public health officials, partners and, most important, customers from across the country, we have only just begun to make significant impact in our core mission: to help people feel safer and get industries and our economy back to full operation. 2022, here we come.”
In addition to securing the renewal of its emergency exemption specific to the current pandemic, Grignard Pure, LLC is currently engaged with the EPA in seeking approval for Grignard Pure™ for nationwide authorization, which would allow for the use of the technology solution in any unoccupied or occupied space, and effective against the COVID-19 virus as well as additional pathogens including other viruses and bacteria.
